Mark Collins - Equities News

Actionable insights straight to your inbox

Mark Collins

Here Are Three Different Types of Exposure to the Gold Mining Space Heading into 2018

Here are three companies that offer different types of exposure to gold mining right now.

5 MIN READ
12/27/2017

Here Are the Drugs That Just Broke the FDA Approval Record

The FDA just beat its own record for drug approvals in one year.

3 MIN READ
12/20/2017

Here’s Why Viking Therapeutics Might Be A Discount Opportunity Stock

Here's a look at why markets are under reacting to the latest Viking data.

3 MIN READ
11/29/2017

Here’s What Sanofi Is Trying to Do In MS With the Latest Deal

Here's a look at Sanofi's latest deal with Principia.

3 MIN READ
11/10/2017

Markets Are Yet to Absorb This Important Veracyte

Here's a look at the latest Veracyte development and what it means for the company.

3 MIN READ
11/02/2017

Vilacto Bio, Inc. and Carmen Electra Are Trying to Launch a Fresh Product Line

Here's a look at Vilacto Bio and its efforts to leverage Carmen Electra's social influence.

5 MIN READ
11/02/2017

Here’s A Near Term Play In Keryx Biopharmaceuticals (NASDAQ:KERX)

Here's a look at an upcoming binary event for Keryx Pharmaceuticals.

3 MIN READ
10/27/2017

While Distracted By Lynparza, Markets Missed This AstraZeneca PLC (AZN) Development

Here's a look at some secondary but still important news from AZN today.

3 MIN READ
10/19/2017

Here’s Why Oramed Pharmaceuticals Is a Stock to Watch Right Now

Here's a look at where Oramed fits into the diabetes landscape.

5 MIN READ
10/10/2017

Here’s What the AstraZeneca and NewLink Genetics Deal Means for Everyone Involved

Here's a look at the latest deal in oncology with a look at the science and what it means for the players involved.

3 MIN READ
09/28/2017